

Medigen Biotechnology Corp. (3176 MEDIGEN)					
SEQ_NO	1	Date of announcement	2023/05/08	Time of announcement	17:53:54
Subject	The Company's 2023 Q1 consolidated financial statements have been approved by the Board of Directors				
Date of events	2023/05/08	To which item it meets	paragraph 31		
Statement	<ol style="list-style-type: none"> 1. Date of the board of directors submitted or approved: 2023/05/08 2. Date of the audit committee approved: 2023/05/08 3. Start and end dates of financial reports or unaudited financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX): 2023/01/01~2023/03/31 4. Operating revenue accumulated from 1/1 to end of the period (thousand NTD): 164,248 5. Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD): 78,189 6. Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD): (241,846) 7. Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD): (257,566) 8. Profit (loss) accumulated from 1/1 to end of the period (thousand NTD): (264,278) 9. Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD): (94,694) 10. Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD): (0.68) 11. Total assets end of the period (thousand NTD): 9,481,190 12. Total liabilities end of the period (thousand NTD): 3,343,189 13. Equity attributable to owners of parent end of the period (thousand NTD): 1,970,831 14. Any other matters that need to be specified: None 				